Pages

Thursday, March 26, 2015

FDA approves new treatment for diabetic retinopathy in patients with diabetic macular edema

... occlusions, both of which cause fluid to leak into the macula resulting in blurred vision. Eylea is marketed by Tarrytown, N.Y.-based Regeneron Pharmaceuticals Inc. Lucentis is marketed by South San Francisco, California-based Genentech, a ...

http://ift.tt/1M3ttn5

No comments:

Post a Comment